AACR 2023: 1C3, A Novel Non-Blocking Anti-Human TNFR2 Antibody, Promotes Effector T Cell Responses and Demonstrates Potent Anti-Tumor Activity
Conclusions
In vitro, BCG003 stimulates the proliferation and activation of hCD8+ T cells, displays ADCC effects on TNFR2–positive cells, and reverses Treg suppression of CD8+ cell proliferation.
BCG003 monotherapy demonstrates anti-tumor activity and enhances tumor inhibition efficacy in combination with anti-PD-1/PD-L1 antibodies. No toxicity was observed in hTNFR2 mice.
Nonclinical toxicological pharmacokinetics studies in cynomolgus monkeys are ongoing, and preliminary data suggest good PK and tolerance of BCG003 in cynomolgus monkeys.
BCG003 binds to the CRD3 and CRD4 domains of TNFR2 without blocking the binding of TNFα.
In vitro, BCG003 stimulates the proliferation and activation of hCD8+ T cells, displays ADCC effects on TNFR2–positive cells, and reverses Treg suppression of CD8+ cell proliferation.
BCG003 monotherapy demonstrates anti-tumor activity and enhances tumor inhibition efficacy in combination with anti-PD-1/PD-L1 antibodies. No toxicity was observed in hTNFR2 mice.
Nonclinical toxicological pharmacokinetics studies in cynomolgus monkeys are ongoing, and preliminary data suggest good PK and tolerance of BCG003 in cynomolgus monkeys.
+86-010-56967680
Copyright © 2024 Biocytogen. All Rights Reserved
Powered by Fractal-technology